Report: All change in the US Pharma Market? TOC

Foreword
EXECUTIVE SUMMARY
Industry Overview
Branded company sales overview
- Leading Originator Companies, Global Pharmaceutical Revenues, 2006-07 (US$ millions)
Exposure to generics
- % of Global Revenues Likely to Face Generic Competition, 2008-12
Branded defence strategies
- Incremental innovation
  - Extended-release formulations
  - Second-generation products
- Citizen petitions
- Deals with generic companies
  - Authorised generics
Biologics
- Leading Originator Companies, PHSA Biologic Revenues 2007
- FDCA biologics
Generic Approvals and Launches
- Pharmaceutical Products Estimated to Face Widespread Generic Competition by 2012
- Pharmaceutical Products Estimated to Face Limited Generic Competition by 2012
- Pharmaceutical Products Estimated to Face No Generic Competition by 2012
- Biologic Products: No Generic Competition to 2012
- 2007 Global Revenues Subject to Generic Competition by 2012 (US$ millions)
Generic launches ' at risk'
- Summary of ' at risk' US Generic Launches, 2006-08
Research-Based Company Profiles
Abbott Laboratories
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (US$ millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Biaxin
- Depakote/Depakote ER
- Humira
- Kaletra
- Omnicef
- Synthroid
- Tricor
A mgen
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (US$ millions)
  - US Product Sales Data, 2006-07 (US$ millions)
- Aranesp
- Epogen
- Neulasta
- Neupogen
- Enbrel
- Sensipar
- Vectibix
AstraZeneca
- Sales Intro
- Exposure to generics 2008-12
- Defence Strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (US$ millions)
  - US Product Sales Data, 2006-07 (US$ millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
  - 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
  - 2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Arimidex
- Atacand
- Casodex
- Crestor
- Nexium
- Prilosec
- Pulmicort
- Seroquel
- Toprol XL
- Zoladex
- Zomig
Boehringer Ingelheim
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (euros millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (euro millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Aggrenox
- Combivent
- Flomax
- Micardis
- Mirapex
- Mobic
- Spiriva
Bristol-Myers Squibb
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (US$ millions)
  - US Product Sales Data, 2006-07 (US$ millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
  - 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (£ billions)
  - 2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Abilify
- Avapro/Avalide
- Baraclude
- Erbitux
- Orencia
- Plavix
- Pravachol
- Reyataz
- Sprycel
- Sustiva
Eli Lilly
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (US$ millions)
  - US Product Sales Data, 2006-07 (US$ millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
  - 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
  - 2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Alimta
- Byetta
- Cialis
- Cymbalta
- Evista
- Forteo
- Gemzar
- Humatrope
- Strattera
- Zyprexa
- Insulin products
GlaxoSmithKline
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (£ millions)
  - US Product Sales Data, 2006-07 (£ millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (£ billions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
  - 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (£ billions)
  - 2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Advair Diskus
- Augmentin
- Avandia
- Avodart
- Combivir
- Coreg
- Epzicom
- Flonase
- Flovent
- Imitrex
- Lamictal
- Paxil
- Requip
- Trizivir
- Valtrex
- Wellbutrin
- Zofran
Johnson & Johnson
- Sales intro
- Exposure to generics 2008-12
- Defence strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (US$ millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Aciphex
- Concerta
- Duragesic
- Levaquin
- Procrit
- Remicade
- Risperdal
- Topamax
Merck & Co
- Sales intro
- Exposure to generics 2008-12
- Defence strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (US$ millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Cancidas
- Cozaar
- Emend
- Fosamax
- Januvia
- Maxalt
- Primaxin
- Proscar/Propecia
- Singulair
- Trusopt/Cosopt
- Zocor
Novartis
- Sales intro
- Exposure to generics 2008-12
- Defence strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (US$ millions)
  - US Product Sales Data, 2006-07 (US$ millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
  - 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
  - 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Diovan
- Exelon
- Famvir
- Femara
- Focalin
- Gleevec
- Lamisil
- Lescol XL
- Lotrel
- Sandostatin
- Trileptal
- Zometa
Pfizer
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (US$ millions)
  - 2007 Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
  - 2007 Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Aricept
- Aromasin
- Caduet
- Camptosar
- Cardura
- Celebrex
- Chantix
- Detrol/Detrol LA
- Genotropin
- Geodon Oral
- Lipitor
- Lyrica
- Neurontin
- Norvasc
- Relpax
- Sutent
- Vfend
- Viagra/Revatio
- Xalatan
- Zithromax
- Zoloft
- Zyrtec
- Zyvox
Roche
- Sales intro
- Exposure to generics 2008-12
- Defence strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (CHF millions)
  - US Product Sales Data, 2006-07 (CHF millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (CHF millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
  - 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (CHF millions)
  - 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Avastin
- Boniva
- CellCept
- Herceptin
- Kytril
- Lucentis
- Nutropin
- Pegasys
- Rituxan
- Tamiflu
- Tarceva
- Valcyte
- Xeloda
- Xenical
- Xolair
Sanofi Aventis
- Sales intro
- Exposure to generics 2008-12
- Defence strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (euro millions)
  - US Product Sales Data, 2006-07 (euro millions)
  - 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (euros millions)
  - 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Actonel
- Allegra
- Amaryl
- Ambien
- Avapro
- Copaxone
- Deprocon
- Eloxatine
- Lantus
- Lovenox
- Nasacort
- Plavix
- Taxotere
- Altace
- Uroxatral
Wyeth
- Sales intro
- Exposure to generics 2008-12
- Defence strategies
  - Product Summary, 2006-2012
  - Summary of Products Reviewed
  - Summary by Year
  - Global Product Sales Data, 2006-07 (US$ millions)
  - US Product Sales Data, 2006-07 (US$ millions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
  - 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
  - 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (£ billions)
  - 2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Effexor
- Prevnar
- Protonix
- Zosyn/Tazocin
- Tygacil
Appendix: Overview of the generic application and approval system
Appendix 1: ANDA Approvals
- ANDA Approvals, 2002-08

All change in the US Pharma Market?

Table of Contents